Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kanako Izumi-Nagai is active.

Publication


Featured researches published by Kanako Izumi-Nagai.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2006

Angiotensin II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal Neovascularization

Norihiro Nagai; Yuichi Oike; Kanako Izumi-Nagai; Takashi Urano; Yoshiaki Kubota; Kousuke Noda; Yoko Ozawa; Makoto Inoue; Kazuo Tsubota; Toshio Suda; Susumu Ishida

Background—Choroidal neovascularization (CNV) is a critical pathogenesis in age-related macular degeneration, the most common cause of blindness in the developed countries. The aim of the current study was to determine the involvement of the renin-angiotensin system (RAS) with the development of CNV, using human surgical samples and the murine model of laser-induced CNV. Methods and Results—In the human and murine CNV tissues, the vascular endothelium expressed angiotensin II type 1 receptor (AT1-R), AT2-R, and angiotensin II. The CNV volume was significantly suppressed by treatment with an AT1-R blocker telmisartan, but not with an AT2-R blocker. AT1-R signaling blockade with telmisartan inhibited various inflammatory mechanisms including macrophage infiltration and upregulation of VEGF, intercellular adhesion molecule-1 (ICAM-1), MCP-1, and IL-6 in the retinal pigment epithelium-choroid complex. A PPAR-&ggr; antagonist partially but significantly reversed the suppressive effect of telmisartan on in vivo induction of CNV and in vitro upregulation of ICAM-1 and MCP-1 in endothelial cells and IL-6 in macrophages, showing the dual contribution of PPAR-&ggr;-agonistic and AT1-R-antagonistic actions in the telmisartan treatment. Conclusions—AT1-R–mediated inflammation plays a pivotal role in the development of CNV, indicating the possibility of AT1-R blockade as a novel therapeutic strategy to inhibit CNV.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2007

Macular Pigment Lutein Is Antiinflammatory in Preventing Choroidal Neovascularization

Kanako Izumi-Nagai; Norihiro Nagai; Kazuhiro Ohgami; Shingo Satofuka; Yoko Ozawa; Kazuo Tsubota; Kazuo Umezawa; Shigeaki Ohno; Yuichi Oike; Susumu Ishida

Background—Choroidal neovascularization (CNV) is a critical pathogenesis in age-related macular degeneration, the most common cause of blindness in the developed countries. The aim of the current study was to investigate the effect of lutein supplementation on the development of the murine model of laser-induced CNV together with underlying molecular mechanisms. Methods and Results—Mice were orally pretreated with lutein daily from 3 days before laser photocoagulation untill the end of the study. The index of CNV volume was significantly suppressed by the treatment with lutein, compared with vehicle-treated animals. Lutein treatment led to significant inhibition of macrophage infiltration into CNV and of the in vivo and in vitro expression of inflammation-related molecules including vascular endothelial growth factor, monocyte chemotactic protein −1, and intercellular adhesion molecule-1. Importantly, lutein suppressed I&kgr;B-α degradation and nuclear translocation of nuclear factor (NF)-&kgr;B p65 both in vivo and in vitro. Additionally, the development of CNV was significantly suppressed by inhibiting NF-&kgr;B p65 nuclear translocation, to the levels seen in the lutein treatment. Conclusions—Lutein treatment led to significant suppression of CNV development together with inflammatory processes including NF-&kgr;B activation and subsequent upregulation of inflammatory molecules, providing molecular evidence of potential validity of lutein supplementation as a therapeutic strategy to suppress CNV.


Investigative Ophthalmology & Visual Science | 2008

Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin

Kanako Izumi-Nagai; Norihiro Nagai; Kazuhiro Ohgami; Shingo Satofuka; Yoko Ozawa; Kazuo Tsubota; Shigeaki Ohno; Yuichi Oike; Susumu Ishida

PURPOSE Astaxanthin (AST) is a carotenoid found in marine animals and vegetables. The purpose of the present study was to investigate the effect of AST on the development of experimental choroidal neovascularization (CNV) with underlying cellular and molecular mechanisms. METHODS Laser photocoagulation was used to induce CNV in C57BL/6J mice. Mice were pretreated with intraperitoneal injections of AST daily for 3 days before photocoagulation, and treatments were continued daily until the end of the study. CNV response was analyzed by volumetric measurements 1 week after laser injury. Retinal pigment epithelium-choroid levels of IkappaB-alpha, intercellular adhesion molecule (ICAM)-1, monocyte chemotactic protein (MCP)-1, interleukin (IL)-6, vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR)-1, and VEGFR-2 were examined by Western blotting or ELISA. AST was applied to capillary endothelial (b-End3) cells, macrophages, and RPE cells to analyze the activation of NF-kappaB and the expression of inflammatory molecules. RESULTS The index of CNV volume was significantly suppressed by treatment with AST compared with that in vehicle-treated animals. AST treatment led to significant inhibition of macrophage infiltration into CNV and of the in vivo and in vitro expression of inflammation-related molecules, including VEGF, IL-6, ICAM-1, MCP-1, VEGFR-1, and VEGFR-2. Importantly, AST suppressed the activation of the NF-kappaB pathway, including IkappaB-alpha degradation and p65 nuclear translocation. CONCLUSIONS AST treatment, together with inflammatory processes including NF-kappaB activation, subsequent upregulation of inflammatory molecules, and macrophage infiltration, led to significant suppression of CNV development. The present study suggests the possibility of AST supplementation as a therapeutic strategy to suppress CNV associated with AMD.


British Journal of Ophthalmology | 2014

Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration

Misa Suzuki; Norihiro Nagai; Kanako Izumi-Nagai; Hajime Shinoda; Takashi Koto; Atsuro Uchida; Hiroshi Mochimaru; Kenya Yuki; Mariko Sasaki; Kazuo Tsubota; Yoko Ozawa

Background/aims To study the initial characteristics and response to intravitreal ranibizumab (IVR) treatment of age-related macular degeneration (AMD). Methods We reviewed the clinical records of 141 eyes in 141 AMD patients who received monthly IVR for 3 months and thereafter pro re nata (PRN) injections for 9 months as the first treatment for AMD. Patients whose best corrected visual acuity (BCVA) worsened at month 12, and those with increased exudative fundus findings after IVR or an increased central retinal thickness of more than 100 μm at month 12, were considered to be non-responders as judged by BCVA and fundus findings, respectively. Non-responders’ initial characteristics were analysed using logistic regression models. Results 14.9% of eyes were non-responders as judged by BCVA, and 17.0% were non-responders as judged by fundus findings. Initial fibrovascular pigment epithelial detachment (PED) (OR 22.9, 95% CI 2.61 to 201) and serous PED (OR 4.12, 95% CI 1.08 to 15.8) were associated with non-response as judged by BCVA. Initial fibrovascular PED (OR 33.5, 95% CI 2.95 to 381) and type 1 choroidal neovascularization (OR 6.46, 95% CI 1.39 to 30.0) were associated with non-response, as judged by fundus findings. Conclusions Although most AMD responded to IVR, non-responders had initial clinical characteristics that might be informative for managing their treatment.


Retina-the Journal of Retinal and Vitreous Diseases | 2015

Association of macular pigment optical density with serum concentration of oxidized low-density lipoprotein in healthy adults

Norihiro Nagai; Kanako Izumi-Nagai; Misa Suzuki; Hajime Shinoda; Takashi Koto; Atsuro Uchida; Hiroshi Mochimaru; Yohei Tomita; Seiji Miyake; Saori Kobayashi; Mariko Sasaki; Kazuo Tsubota; Yoko Ozawa

Purpose: To analyze the association between macular pigment optical density (MPOD), which reflects lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) in the macula, and background characteristics. Methods: Fifty-five healthy adult volunteers were analyzed. Macular pigment optical density was measured using a heterochromatic flicker photometry technique, and serum concentrations of carotenoids and lipoproteins were by high-performance liquid chromatography and enzyme-linked immunosorbent assay, respectively. Dietary intake of nutrient was determined by a validated self-administered questionnaire on ingestion frequency. Results: Macular pigment optical density was positively correlated with serum concentrations of L and Z and dietary L intake and inversely correlated with serum oxidized low-density lipoprotein (LDL). Although MPOD decreased with age (95% confidence interval, −0.011 to −0.002; correlation coefficient, −0.269; P = 0.007), serum L/Z and dietary L intake did not. In contrast, serum oxidized LDL was positively correlated with age (95% confidence interval, 0.69–2.34; correlation coefficient, 0.333; P = 0.0004). After adjusting for age, sex, and oxidized LDL, serum L was positively correlated with MPOD (95% confidence interval, 0.88–1.69; P = 0.000001). After adjusting for age, sex, and serum L, serum oxidized LDL was inversely correlated with MPOD (95% confidence interval, −0.002 to −0.0004; P = 0.006). Conclusion: Macular pigment optical density was inversely correlated with serum oxidized LDL. Further study to know the impact of oxidized LDL on MPOD may be warranted.


Optometry and Vision Science | 2015

Functional Visual Acuity in Age-Related Macular Degeneration.

Yohei Tomita; Norihiro Nagai; Misa Suzuki; Hajime Shinoda; Atsuro Uchida; Hiroshi Mochimaru; Kanako Izumi-Nagai; Mariko Sasaki; Kazuo Tsubota; Yoko Ozawa

Purpose We evaluated whether a functional visual acuity (FVA) system can detect subtle changes in central visual acuity that reflect pathological findings associated with age-related macular degeneration (AMD). Methods Twenty-eight patients with unilateral AMD and logMAR monocular best corrected VA better than 0 in both eyes, as measured by conventional chart examination, were analyzed between November 2012 and April 2013. After measuring conventional VA, FVA, and contrast VA with best correction, routine eye examinations including spectral domain–optical coherence tomography were performed. Standard Schirmer test was performed, and corneal and lens densities were measured. Results The FVA score (p < 0.001) and visual maintenance ratio (p < 0.001) measured by the FVA system, contrast VA (p < 0. 01), and conventional VA (p < 0.01) were significantly worse in the AMD-affected eyes than in the fellow eyes. No significant differences were observed in the anterior segment conditions. Forward stepwise regression analysis demonstrated that the length of interdigitation zone disruption, as visualized by optical coherence tomography imaging, correlated with the FVA score (p < 0.01) but not with any other parameters investigated. Conclusions The FVA system detects subtle changes in best corrected VA in AMD-affected eyes and reflects interdigitation zone disruption, an anatomical change in the retina recorded by optical coherence tomography. Further studies are required to understand the value of the FVA system in detecting subtle changes in AMD.


Acta Ophthalmologica | 2016

Sneddon's syndrome with optic disc macroaneurysm and macular edema successfully treated with subtenon steroid injection

Norihiro Nagai; Yuka Ohta; Kanako Izumi-Nagai; Hajime Shinoda; Kazuo Tsubota; Yoko Ozawa

tified, and the severity and classification of disease correlate approximately with genotype. In this case, we found a novel mutation c.2T>A in exon 2 responsible for ND resulting in a missense mutation. The mutation affecting the initiation codon produced an AAG codon, which could not initiate translation. As the translation start site and its context sequence play an important role in the control of translation efficiency and the correct translation of mRNA, the c.2T>A mutation is expected to cause the failure of the start of ND gene translation or the production of an aberrant protein. Previous reported initiation codon point mutations, c.1_2delAAT, c.2_3delTG, c.1A>G (p.Met1Val) and c.2T>G (p.Met1Arg), have been reported to be responsible for ND (Isashiki et al. 1995; Schuback et al. 1995; Caballero et al. 1996; Zhang et al. 2013). All these patients have congenital blindness. The patients with c.1_2delAAT, c.2_3delTG and c.1A>G mutation remained unremarkable in ontological and neurological studies, while the patient with c.2T>G mutation had hearing loss and autistic features. In this case, both hearing problems and mental retardation were absent in two patients. We suppose that the differences in the mutations and the subsequent differences in the translation efficiency and aberrant protein products may contribute to the differences in clinical manifestation. In summary, we reported a novel missense NDP mutation of a familial case of ND in a Chinese family.


Investigative Ophthalmology & Visual Science | 2007

Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-κB pathway

Norihiro Nagai; Kanako Izumi-Nagai; Yuichi Oike; Takashi Koto; Shingo Satofuka; Yoko Ozawa; Kenji Yamashiro; Makoto Inoue; Kazuo Tsubota; Kazuo Umezawa; Susumu Ishida


American Journal of Pathology | 2007

Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization

Kanako Izumi-Nagai; Norihiro Nagai; Yoko Ozawa; Masahiko Mihara; Yoshiyuki Ohsugi; Toshihide Kurihara; Takashi Koto; Shingo Satofuka; Makoto Inoue; Kazuo Tsubota; Hideyuki Okano; Yuichi Oike; Susumu Ishida


Investigative Ophthalmology & Visual Science | 2007

Eicosapentaenoic acid is anti-inflammatory in preventing choroidal neovascularization in mice

Takashi Koto; Norihiro Nagai; Hiroshi Mochimaru; Toshihide Kurihara; Kanako Izumi-Nagai; Shingo Satofuka; Hajime Shinoda; Kousuke Noda; Yoko Ozawa; Makoto Inoue; Kazuo Tsubota; Yuichi Oike; Susumu Ishida

Collaboration


Dive into the Kanako Izumi-Nagai's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge